Home
Our Approach
Board of directors
Scientific Advisors
Collaborations
Stakeholders
Further readings
Our Vision
Pipeline
News
Contact

HARTIS Pharma

Home
Our Approach
Board of directors
Scientific Advisors
Collaborations
Stakeholders
Further readings
Our Vision
Pipeline
News
Contact
  • Company Overview
  • Board of directors
  • Scientific Advisors
  • Collaborations
  • Stakeholders
  • Further readings
  • The Foundation for Sickle Cell Disease Research, which supports and promotes hemoglobinopathy research.

  • oneSCDvoice, an education platform that gathers credible disease information and empowers people impacted by SCD.

  • Sickle Cell Disease, a platform to support the sickle cell community.

  • SOS Globi, Fédération des Malades Drépanocytaires et Thalassémiques.

  • APIPD, Association Pour l’Information et la Prévention de la Drépanocytose.

  • Haemoglobinopathie.ch, the Swiss Haemoglobinopathy Platform.

  • https://www.rethinksicklecelldisease.com/

  • Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease, Niesor & al. 2015.

  • Potential Signal Transduction Regulation by HDL of the β2-Adrenergic Receptor Pathway. Implications in Selected Pathological Situations, Niesor & Benghozi, 2015.

  • Orphanet, Journal of Rare Diseases.

Back to Top
Hartis Pharma, 13C Chemin de Bonmont, Nyon, VD, 1260, Suisse

contact@hartispharma.com